0000899243-21-009554.txt : 20210303 0000899243-21-009554.hdr.sgml : 20210303 20210303194636 ACCESSION NUMBER: 0000899243-21-009554 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON DAVID LEE CENTRAL INDEX KEY: 0001733883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 21711754 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS STREET 2: 171 OYSTER POINT BLVD, STE. 300 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001733883 JOHNSON DAVID LEE C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Commercial Officer Common Stock 2021-02-28 5 A 0 E 375 36.21 A 27407 D Stock Option (Right to Buy) 44.48 2021-03-01 4 A 0 38739 0.00 A 2031-02-28 Common Stock 38739 38739 D Restricted Stock Units 2021-03-01 4 A 0 22102 0.00 A Common Stock 22102 22102 D Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Tricia Suvari, Attorney-in-Fact 2021-03-03